Overview Dividends

(ACHC) Acadia Healthcare - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00404A1097

Inpatient, Residential, Outpatient, Therapy

ACHC EPS (Earnings per Share)

EPS Growth (3Y CAGR): -21.94%
EPS Trend (3Y Correlation): -53.7%

ACHC Revenue

Revenue Growth (3Y CAGR): 10.12%
Revenue Trend (3Y Correlation): 91.3%

Description: ACHC Acadia Healthcare

Acadia Healthcare Company Inc (NASDAQ:ACHC) is a US-based healthcare company operating in the Health Care Facilities sub-industry. The companys stock is classified as common stock.

To evaluate ACHCs performance, key financial metrics are crucial. The companys Market Cap stands at $1942.86M USD, indicating a mid-cap status. The Price-to-Earnings (P/E) ratio is 10.34, suggesting a relatively low valuation compared to its earnings. The Forward P/E ratio is even lower at 7.99, implying expected earnings growth. Return on Equity (RoE) is 6.20%, indicating a moderate return for shareholders.

Key drivers for ACHCs financial performance include occupancy rates, revenue per patient, and operating expenses. As a healthcare facilities operator, ACHCs revenue is largely driven by patient volume and reimbursement rates from government programs and private insurers. The companys ability to manage costs, such as labor and facility expenses, will significantly impact its profitability. Additionally, regulatory changes and healthcare reform efforts can affect ACHCs business model and financials.

To further assess ACHCs potential, monitoring KPIs such as same-store sales growth, patient satisfaction scores, and debt-to-equity ratio will be essential. The companys ability to adapt to changing healthcare landscapes, including shifts towards value-based care and outpatient services, will also be critical to its long-term success.

ACHC Stock Overview

Market Cap in USD	1,944m
Sub-Industry	Health Care Facilities
IPO / Inception	1994-03-04

ACHC Stock Ratings

Growth Rating	-72.2%
Fundamental	53.1%
Dividend Rating	-
Return 12m vs S&P 500	-76.2%
Analyst Rating	4.36 of 5

ACHC Dividends

Currently no dividends paid

ACHC Growth Ratios

Growth Correlation 3m	-13%
Growth Correlation 12m	-90.8%
Growth Correlation 5y	-6.9%
CAGR 5y	-35.32%
CAGR/Max DD 3y	-0.44
CAGR/Mean DD 3y	-1.78
Sharpe Ratio 12m	-0.64
Alpha	0.00
Beta	0.997
Volatility	61.53%
Current Volume	3299.2k
Average Volume 20d	2263.5k
Stop Loss	20.8 (-5.1%)
Signal	0.22

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (139.2m TTM) > 0 and > 6% of Revenue (6% = 193.8m TTM)

FCFTA 0.00 (>2.0%) and ΔFCFTA -0.18pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 5.20% (prev 3.23%; Δ 1.97pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 424.8m > Net Income 139.2m (YES >=105%, WARN >=100%)

Net Debt (2.25b) to EBITDA (498.6m) ratio: 4.52 <= 3.0 (WARN <= 3.5)

Current Ratio 1.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (90.4m) change vs 12m ago -1.75% (target <= -2.0% for YES)

Gross Margin 81.24% (prev 41.19%; Δ 40.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 53.89% (prev 53.84%; Δ 0.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 2.61 (EBITDA TTM 498.6m / Interest Expense TTM 124.3m) >= 6 (WARN >= 3)

Altman Z'' 0.86

(A) 0.03 = (Total Current Assets 691.6m - Total Current Liabilities 523.7m) / Total Assets 6.31b

(B) 0.06 = Retained Earnings (Balance) 375.4m / Total Assets 6.31b

(D) 0.12 = Book Value of Equity 376.3m / Total Liabilities 3.08b

Total Rating: 0.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 53.14

1. Piotroski 3.50pt = -1.50

2. FCF Yield 0.76% = 0.38

3. FCF Margin 0.96% = 0.24

4. Debt/Equity 0.74 = 2.23

5. Debt/Ebitda 4.59 = -2.50

6. ROIC - WACC (= -0.20)% = -0.25

7. RoE 4.56% = 0.38

8. Rev. Trend 91.32% = 6.85

9. EPS Trend -53.72% = -2.69

What is the price of ACHC shares?

As of September 18, 2025, the stock is trading at USD 21.92 with a total of 3,299,249 shares traded.
Over the past week, the price has changed by +4.11%, over one month by +3.74%, over three months by +5.13% and over the past year by -71.81%.

Is Acadia Healthcare a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Acadia Healthcare is currently (September 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 53.14 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACHC is around 17.24 USD . This means that ACHC is currently overvalued and has a potential downside of -21.35%.

Is ACHC a buy, sell or hold?

Acadia Healthcare has received a consensus analysts rating of 4.36. Therefore, it is recommended to buy ACHC.

Strong Buy: 9
Buy: 1
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ACHC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	30.3	38.2%
Analysts Target Price	30.3	38.2%
ValueRay Target Price	18.6	-15%

Last update: 2025-09-11 04:30

ACHC Fundamental Data Overview

Market Cap USD = 1.94b (1.94b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 131.4m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 13.852
P/E Forward = 8.8574
P/S = 0.602
P/B = 0.6991
P/EG = 1.32
Beta = 0.893
Revenue TTM = 3.23b USD
EBIT TTM = 324.4m USD
EBITDA TTM = 498.6m USD
Long Term Debt = 2.25b USD (from longTermDebt, last quarter)
Short Term Debt = 44.0m USD (from shortTermDebt, last quarter)
Debt = 2.29b USD (Calculated: Short Term 44.0m + Long Term 2.25b)
Net Debt = 2.25b USD (from netDebt column, last quarter)
Enterprise Value = 4.10b USD (1.94b + Debt 2.29b - CCE 131.4m)
Interest Coverage Ratio = 2.61 (Ebit TTM 324.4m / Interest Expense TTM 124.3m)
FCF Yield = 0.76% (FCF TTM 31.1m / Enterprise Value 4.10b)
FCF Margin = 0.96% (FCF TTM 31.1m / Revenue TTM 3.23b)
Net Margin = 4.31% (Net Income TTM 139.2m / Revenue TTM 3.23b)
Gross Margin = 81.24% ((Revenue TTM 3.23b - Cost of Revenue TTM 606.0m) / Revenue TTM)
Tobins Q-Ratio = 10.91 (Enterprise Value 4.10b / Book Value Of Equity 376.3m)
Interest Expense / Debt = 1.53% (Interest Expense 35.1m / Debt 2.29b)
Taxrate = 22.64% (77.4m / 341.9m)
NOPAT = 250.9m (EBIT 324.4m * (1 - 22.64%))
Current Ratio = 1.32 (Total Current Assets 691.6m / Total Current Liabilities 523.7m)
Debt / Equity = 0.74 (Debt 2.29b / last Quarter total Stockholder Equity 3.08b)
Debt / EBITDA = 4.59 (Net Debt 2.25b / EBITDA 498.6m)
Debt / FCF = 73.72 (Debt 2.29b / FCF TTM 31.1m)
Total Stockholder Equity = 3.06b (last 4 quarters mean)
RoA = 2.21% (Net Income 139.2m, Total Assets 6.31b )
RoE = 4.56% (Net Income TTM 139.2m / Total Stockholder Equity 3.06b)
RoCE = 6.12% (Ebit 324.4m / (Equity 3.06b + L.T.Debt 2.25b))
RoIC = 4.89% (NOPAT 250.9m / Invested Capital 5.13b)
WACC = 5.09% (E(1.94b)/V(4.24b) * Re(9.69%)) + (D(2.29b)/V(4.24b) * Rd(1.53%) * (1-Tc(0.23)))
Shares Correlation 3-Years: 29.01 | Cagr: -0.13%
Discount Rate = 9.69% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 63.39% ; FCFE base≈33.9m ; Y1≈22.3m ; Y5≈10.2m
Fair Price DCF = 1.69 (DCF Value 155.8m / Shares Outstanding 92.3m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -53.72 | EPS CAGR: -21.94% | SUE: 2.89 | # QB: 2
Revenue Correlation: 91.32 | Revenue CAGR: 10.12% | SUE: N/A | # QB: None

Additional Sources for ACHC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle